Log in

Relevant bibliographies by topics / Therapeutic enzymes / Journal articles

To see the other types of publications on this topic, follow the link: Therapeutic enzymes.

Journal articles on the topic 'Therapeutic enzymes'

Author: Grafiati

Published: 4 June 2021

Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Therapeutic enzymes.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Städler, Brigitte, and Alexander N. Zelikin. "Enzyme prodrug therapies and therapeutic enzymes." Advanced Drug Delivery Reviews 118 (September 2017): 1. http://dx.doi.org/10.1016/j.addr.2017.10.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zhu, Chen-Yuan, Fei-Long Li, Ye-Wang Zhang, Rahul K. Gupta, Sanjay K. S. Patel, and Jung-Kul Lee. "Recent Strategies for the Immobilization of Therapeutic Enzymes." Polymers 14, no. 7 (2022): 1409. http://dx.doi.org/10.3390/polym14071409.

Full text

Abstract:

Therapeutic enzymes play important roles in modern medicine due to their high affinity and specificity. However, it is very expensive to use them in clinical medicine because of their low stability and bioavailability. To improve the stability and effectiveness of therapeutic enzymes, immobilization techniques have been employed to enhance the applications of therapeutic enzymes in the past few years. Reported immobilization techniques include entrapment, adsorption, and covalent attachment. In addition, protein engineering is often used to improve enzyme properties; however, all methods prese

APA, Harvard, Vancouver, ISO, and other styles

3

Noten, J. B. G. M., W. M. A. Verhoeven, S. Tuinier, and D. Touw. "Therapeutic drug monitoring." Acta Neuropsychiatrica 11, no. 1 (1999): 15–16. http://dx.doi.org/10.1017/s0924270800036309.

Full text

Abstract:

SUMMARYThe cytochrome P450 iso-enzyme system plays a key role in the biotransformation of many drugs, including psychotropics. Its activity is determined by both genetic and environmental factors. The most important iso-enzymes for psychiatry in general are P450 IID6, 3A4 and 1A2. Knowledge about the involvement of these enzymes and biotransformation processes is mandatory because of the individual variability in their metabolic capacity. Regular measurement of plasmaconcentrations of (psycho)pharmacological compounds is therefore essential. In addition, the potential value of pheno- and/or ge

APA, Harvard, Vancouver, ISO, and other styles

4

Bax, Bridget E. "Erythrocytes as Carriers of Therapeutic Enzymes." Pharmaceutics 12, no. 5 (2020): 435. http://dx.doi.org/10.3390/pharmaceutics12050435.

Full text

Abstract:

Therapeutic enzymes are administered for the treatment of a wide variety of diseases. They exert their effects through binding with a high affinity and specificity to disease-causing substrates to catalyze their conversion to a non-noxious product, to induce an advantageous physiological change. However, the metabolic and clinical efficacies of parenterally or intramuscularly administered therapeutic enzymes are very often limited by short circulatory half-lives and hypersensitive and immunogenic reactions. Over the past five decades, the erythrocyte carrier has been extensively studied as a s

APA, Harvard, Vancouver, ISO, and other styles

5

Dahikar, S. B., and S. A. Bhutada. "DNA Repair Enzymes as Therapeutic Agents: a Review." Mikrobiolohichnyi Zhurnal 84, no. 1 (2021): 65–71. http://dx.doi.org/10.15407/microbiolj84.01.065.

Full text

Abstract:

DNA damage is long recognized factor for development and progression of cancer in humans. Genome instability is the leading factor behind development of cancer. There are some DNA repair pathways and DNA damage checkpoints present in all creatures, without them the functional stability gets compromised. Impaired DNA repair results in genomic instability leading to development of cancer, limited lifespan, early ageing. UV rays and Ionizing radiations are the major exogenous forces responsible for DNA damage, causing lesions in DNA. These lesions are cause of photoageing. Protection administered

APA, Harvard, Vancouver, ISO, and other styles

6

Amber, S. Gad. "Some Important Therapeutic Enzymes and their Uses." Chemistry Research Journal 5, no. 3 (2020): 165–72. https://doi.org/10.5281/zenodo.12589362.

Full text

Abstract:

<strong>Abstract </strong>Enzymes are protein molecules that are responsible for many vital reactions including digesting food, building bones, purifying blood and detoxification. Enzymes also, have several clinical uses in treatments including leukemia, metabolic disorders, inflammation, cardiovascular disease and lysosomal storage diseases etc. Specificity, stability, and substrate conversion makes therapeutic enzymes advisable agents more than non-enzymatic drugs. As foreign proteins to the body, enzymes are representing antigenicity that can induce immune response which lead to immuno

APA, Harvard, Vancouver, ISO, and other styles

7

Zbar, Nedhaal Suhail. "A Review Article: Protein Engineering of Therapeutic Enzymes." International Journal for Research in Applied Sciences and Biotechnology 9, no. 1 (2022): 140–51. http://dx.doi.org/10.31033/ijrasb.9.1.16.

Full text

Abstract:

Through the development of advanced, stimulus-responsive pharmacological systems, protein engineering has the potential to alter the metabolic drug landscapes. Protein therapies are a fast growing category of FDA-approved medications that have the potential to improve clinical consequences in the long run. Protein therapeutics engineering is still in its preliminary phase; however recent advancements in protein engineering skills are being used to gain direct monitoring over pharmacodynamics. Drugs that are intended to be metabolized under specific conditions are known as stimulus-responsive p

APA, Harvard, Vancouver, ISO, and other styles

8

Wiederschain, G. Ya, and M. Baldry. "Directory of therapeutic enzymes." Biochemistry (Moscow) 71, no. 11 (2006): 1289–90. http://dx.doi.org/10.1134/s0006297906110162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Alisi, Anna, Sara Tomaselli, Clara Balsano, and Angela Gallo. "Hepatitis C virus therapeutics: Editing enzymes promising therapeutic targets?" Hepatology 54, no. 2 (2011): 742. http://dx.doi.org/10.1002/hep.24409.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Sioud, Mouldy, and Marianne Leirdal. "Therapeutic RNA and DNA enzymes." Biochemical Pharmacology 60, no. 8 (2000): 1023–26. http://dx.doi.org/10.1016/s0006-2952(00)00395-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Maximov, V., V. Reukov, and A. A. Vertegel. "Targeted delivery of therapeutic enzymes." Journal of Drug Delivery Science and Technology 19, no. 5 (2009): 311–20. http://dx.doi.org/10.1016/s1773-2247(09)50066-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Kokotos, George. "Lipolytic enzymes as therapeutic targets." European Journal of Lipid Science and Technology 110, no. 12 (2008): 1081–83. http://dx.doi.org/10.1002/ejlt.200800249.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Cruz, Maria Eugénia Meirinhos, Maria Luísa Corvo, Maria Bárbara Martins, Sandra Simões, and Maria Manuela Gaspar. "Liposomes as Tools to Improve Therapeutic Enzyme Performance." Pharmaceutics 14, no. 3 (2022): 531. http://dx.doi.org/10.3390/pharmaceutics14030531.

Full text

Abstract:

The drugs concept has changed during the last few decades, meaning the acceptance of not only low molecular weight entities but also macromolecules as bioagent constituents of pharmaceutics. This has opened a new era for a different class of molecules, namely proteins in general and enzymes in particular. The use of enzymes as therapeutics has posed new challenges in terms of delivery and the need for appropriate carrier systems. In this review, we will focus on enzymes with therapeutic properties and their applications, listing some that reached the pharmaceutical market. Problems associated

APA, Harvard, Vancouver, ISO, and other styles

14

Sony, Sharlet E., E. Muralinath, Naidu K. Mohan, et al. "Understanding Enzyme Inhibitors: Their Dual Role as Poisons and Drugs." Research and Reviews: Journal of Forensic Nursing 2, no. 2 (2024): 18–25. https://doi.org/10.5281/zenodo.12623888.

Full text

Abstract:

<em>Enzymes, the biological catalysts responsible for enhancing chemical reactions within living organisms, are critical for regulating life-sustaining processes. </em><em>Whatever it may be, </em><em>the modulation of enzyme activity is not only of interest in physiological contexts but also holds significance in pharmacology and toxicology. Enzyme inhibitors play a</em><em>n important </em><em>role in both realms, </em><em>behaving </em><em>as potent poisons, therapeutic drugs and even as therapeutic enzymes themselves.</em>

APA, Harvard, Vancouver, ISO, and other styles

15

Qi, Hongzhao, Jie Yang, Jie Yu, et al. "Glucose-responsive nanogels efficiently maintain the stability and activity of therapeutic enzymes." Nanotechnology Reviews 11, no. 1 (2022): 1511–24. http://dx.doi.org/10.1515/ntrev-2022-0095.

Full text

Abstract:

Abstract To date, the encapsulation of therapeutic enzymes in a protective matrix is an optimized strategy for the maintenance of their stability, facilitating their clinical application. However, the stability and activity of therapeutic enzymes are often in tension with each other. A rigid protective matrix may effectively maintain the stability of therapeutic enzymes, but it can reduce the diffusion of substrates toward the therapeutic enzyme active site, dramatically affecting their catalytic efficiency. Here, we exploited a kind of nanogels by in situ polymerization on the arginine deimin

APA, Harvard, Vancouver, ISO, and other styles

16

Eckman, E. A., та C. B. Eckman. "Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention". Biochemical Society Transactions 33, № 5 (2005): 1101–5. http://dx.doi.org/10.1042/bst0331101.

Full text

Abstract:

The accumulation of Aβ (amyloid β-protein) peptides in the brain is a pathological hallmark of all forms of AD (Alzheimer's disease) and reducing Aβ levels can prevent or reverse cognitive deficits in mouse models of the disease. Aβ is produced continuously and its concentration is determined in part by the activities ofseveral degradative enzymes, including NEP (neprilysin), IDE (insulin-degrading enzyme), ECE-1 (endothelinconverting enzyme 1) and ECE-2, and probably plasmin. Decreased activity of any of these enzymes due to genetic mutation, or age- or disease-related alterations in gene exp

APA, Harvard, Vancouver, ISO, and other styles

17

Gubergrits, N. B., N. V. Byelyayeva, A. Y. Klochkov, G. М. Lukashevish, and P. G. Fomenko. "Advantages and therapeutic capacities of digestive enzymes preparations of non-animal origin." Bulletin of the Club of Pancreatologists 39, no. 1 (2018): 16–21. http://dx.doi.org/10.33149/vkp.2018.01.03.

Full text

Abstract:

The article presents a literature review on the features and benefits of digestive enzymes preparations of non-animal origin, i.e. drugs which include plant, microbial or fungal enzymes. Diseases and conditions upon which such drugs are prescribed have been pathogenetically substantiated. The results of evidence studies are presented, the outcomes of which conclude that the biotechnological enzyme preparation of bacterial origin is effective and safe in the treatment of cystic fibrosis. Peculiar attention is paid to Digest 365 that contains not only amylo-, proteo- and lipolytic enzymes, but a

APA, Harvard, Vancouver, ISO, and other styles

18

Hadley, K., D. Lindemann, and P. Sato. "Heterologous immunoprecipitates also have potential for therapeutic use." Biotechnology and Applied Biochemistry 9, no. 1 (1987): 1–11. http://dx.doi.org/10.1111/j.1470-8744.1987.tb00457.x.

Full text

Abstract:

Potential therapeutic usefulness of administered enzymes is limited by toxicity and allergenicity. To overcome these problems we are using scurvy to test various enzyme modifications that may be suitable for therapy. L‐Gulonolactone oxidase, which catalyzes the final step in ascorbic acid biosynthesis, is immunoprecipitated with specific antisera from rabbits and then cross‐linked with glutaraldehyde. The modified enzyme retains activity sufficient to elicit ascorbic acid synthesis in scorbutic guinea pigs. Intraperitoneal injection of this altered enzyme to animals supplemented with L‐gulonol

APA, Harvard, Vancouver, ISO, and other styles

19

López-Cortés, Georgina I., Miryam Palacios-Pérez, Margarita M. Hernández-Aguilar, Hannya F. Veledíaz, and Marco V. José. "Human Coronavirus Cell Receptors Provide Challenging Therapeutic Targets." Vaccines 11, no. 1 (2023): 174. http://dx.doi.org/10.3390/vaccines11010174.

Full text

Abstract:

Coronaviruses interact with protein or carbohydrate receptors through their spike proteins to infect cells. Even if the known protein receptors for these viruses have no evolutionary relationships, they do share ontological commonalities that the virus might leverage to exacerbate the pathophysiology. ANPEP/CD13, DPP IV/CD26, and ACE2 are the three protein receptors that are known to be exploited by several human coronaviruses. These receptors are moonlighting enzymes involved in several physiological processes such as digestion, metabolism, and blood pressure regulation; moreover, the three p

APA, Harvard, Vancouver, ISO, and other styles

20

Zhang, Weisheng, Min Chen, David B. West, and Anthony F. Purchio. "Visualizing Drug Efficacy In Vivo." Molecular Imaging 4, no. 2 (2005): 153535002005051. http://dx.doi.org/10.1162/15353500200505109.

Full text

Abstract:

Many enzymes are therapeutic targets for drug discovery, whereas other enzymes are important for understanding drug metabolism and pharmacokinetics during compound testing in animals. Testing of drug efficacy and metabolism in an animal model requires the measurement of disease endpoints as well as assays of enzyme activity in specific tissues at selected time points during treatment. This requires the removal of tissue and biochemical assays. Techniques to noninvasively assess drug effects on enzyme activity using imaging technology would facilitate understanding of drug efficacy, pharmacokin

APA, Harvard, Vancouver, ISO, and other styles

21

P, Keerthi, Lathif AK, and Nesaghi Amuthavel. "Enzyme Technology for Drug Discovery." Journal of Chemical Engineering & Process Technology 14, no. 14 (2023): 8. https://doi.org/10.35248/2157-7048.23.14.471.

Full text

Abstract:

Enzymes are biochemical catalysts that facilitate chemical reactions under Physiological conditions. Currently enzymes are being employed in industrial biotechnology for numerous purposes for the production of novel and sustainable products at a speedy rate. Enzyme technology is the change of an enzyme's structure or catalytic activity in order to produce new metabolites or participate in new reaction pathways. Simultaneously, significant technical advancements are encouraging the chemical and pharmaceutical sectors to embrace enzyme technology, a movement fueled by worries about health, energ

APA, Harvard, Vancouver, ISO, and other styles

22

Azmi, Wamik, and Shabnam Chaudhary. "ARTHROBACTER AS BIOFACTORY OF THERAPEUTIC ENZYMES." International Journal of Pharmacy and Pharmaceutical Sciences 10, no. 11 (2018): 1. http://dx.doi.org/10.22159/ijpps.2018v10i11.25933.

Full text

Abstract:

Therapeutic enzymes are proteins which can be used to treat rare and deadly diseases. They represent a small but profitable market. Therapeutic enzymes are superior to non-enzymatic drugs owing to their high specificity toward the target and also their ability to multiple substrate conversion. They are essential for speeding up all the metabolic processes and many a life-supporting chemical inter-conversions. Actinomycetes including Arthrobacter form an enormous reservoir of secondary metabolites and enzymes. The characterization of L-asparaginase, β-glucosidase, urate oxidase, methionine γ-ly

APA, Harvard, Vancouver, ISO, and other styles

23

Prashith Kekuda, T. R., D. Lavanya, and Rao Pooja. "Lichens as promising resources of enzyme inhibitors: A review." Journal of Drug Delivery and Therapeutics 9, no. 2-s (2019): 665–76. http://dx.doi.org/10.22270/jddt.v9i2-s.2546.

Full text

Abstract:

Inhibition of some enzymes seems to be one of the therapeutic strategies for the management of certain diseases or conditions such as diabetes, Alzheimer’s disease, cancer and obesity. In this review, an updated information on the enzyme inhibitory activity of lichen extracts and lichen compounds by an intensive literature survey is presented. Crude solvent extracts and isolated compounds from lichens were shown to be effective in causing inhibition of several enzymes such as amylase, lipase, lipoxygenase, aromatase, cyclooxygenase, trypsin, β-glucoronidase, prolyl endopeptidase, monoamine oxi

APA, Harvard, Vancouver, ISO, and other styles

24

Aliyev, Tofiq, and Səbrin Abdullayeva. "The Role of Enzymes in Modern Medicine: Advances, Applications, and Future Directions." Luminis Applied Science and Engineering 2, no. 1 (2025): 72–76. https://doi.org/10.69760/lumin.20250001012.

Full text

Abstract:

Enzymes play a critical role in modern medicine, serving as essential biological catalysts in therapeutic and diagnostic applications. This article explores the use of enzymes in enzyme replacement therapy (ERT), pharmaceutical drug development, and clinical diagnostics. The advancements in biotechnology have led to the development of engineered enzymes with improved stability and efficiency, addressing challenges such as enzyme degradation, immunogenicity, and production costs. Recent innovations, including enzyme immobilization, nanotechnology-based delivery systems, and CRISPR-engineered en

APA, Harvard, Vancouver, ISO, and other styles

25

Hossam Abdelmonem, Basma, Noha M. Abdelaal, Eman K. E. Anwer, et al. "Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review." Biomedicines 12, no. 7 (2024): 1467. http://dx.doi.org/10.3390/biomedicines12071467.

Full text

Abstract:

Cytochrome P450 (CYP450) is a group of enzymes that play an essential role in Phase I metabolism, with 57 functional genes classified into 18 families in the human genome, of which the CYP1, CYP2, and CYP3 families are prominent. Beyond drug metabolism, CYP enzymes metabolize endogenous compounds such as lipids, proteins, and hormones to maintain physiological homeostasis. Thus, dysregulation of CYP450 enzymes can lead to different endocrine disorders. Moreover, CYP450 enzymes significantly contribute to fatty acid metabolism, cholesterol synthesis, and bile acid biosynthesis, impacting cellul

APA, Harvard, Vancouver, ISO, and other styles

26

Kaplan, Jeffrey B. "Therapeutic Potential of Biofilm-Dispersing Enzymes." International Journal of Artificial Organs 32, no. 9 (2009): 545–54. http://dx.doi.org/10.1177/039139880903200903.

Full text

Abstract:

Surface-attached colonies of bacteria known as biofilms play a major role in the pathogenesis of medical device infections. Biofilm colonies are notorious for their resistance to antibiotics and host defenses, which makes most device infections difficult or impossible to eradicate. Bacterial cells in a biofilm are held together by an extracellular polymeric matrix that is synthesized by the bacteria themselves. Enzymes that degrade biofilm matrix polymers have been shown to inhibit bio film formation, detach established bio film colonies, and render biofilm cells sensitive to killing by antimi

APA, Harvard, Vancouver, ISO, and other styles

27

Dean, Scott N., Kendrick B. Turner, Igor L. Medintz, and Scott A. Walper. "Targeting and delivery of therapeutic enzymes." Therapeutic Delivery 8, no. 7 (2017): 577–95. http://dx.doi.org/10.4155/tde-2017-0020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Tandon, Siddhi, Anjali Sharma, Shikha Singh, Sumit Sharma, and Saurabh Jyoti Sarma. "Therapeutic enzymes: Discoveries, production and applications." Journal of Drug Delivery Science and Technology 63 (June 2021): 102455. http://dx.doi.org/10.1016/j.jddst.2021.102455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Haeggström, Jesper Z. "Leukotriene biosynthetic enzymes as therapeutic targets." Journal of Clinical Investigation 128, no. 7 (2018): 2680–90. http://dx.doi.org/10.1172/jci97945.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Nakamura, Hiroyuki. "Ceramide metabolism enzymes as therapeutic targets." Proceedings for Annual Meeting of The Japanese Pharmacological Society 96 (2022): 1—B—S09–4. http://dx.doi.org/10.1254/jpssuppl.96.0_1-b-s09-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Couture, Frédéric. "Therapeutic Targeting of the Proteolytic Enzymes." International Journal of Molecular Sciences 24, no. 1 (2022): 521. http://dx.doi.org/10.3390/ijms24010521.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Meghwanshi, Gautam Kumar, Navpreet Kaur, Swati Verma, et al. "Enzymes for pharmaceutical and therapeutic applications." Biotechnology and Applied Biochemistry 67, no. 4 (2020): 586–601. http://dx.doi.org/10.1002/bab.1919.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Mishra, Abhinav P., Suresh Chandra, Ruchi Tiwari, Ashish Srivastava, and Gaurav Tiwari. "Therapeutic Potential of Prodrugs Towards Targeted Drug Delivery." Open Medicinal Chemistry Journal 12, no. 1 (2018): 111–23. http://dx.doi.org/10.2174/1874104501812010111.

Full text

Abstract:

In designing of Prodrugs, targeting can be achieved in two ways: site-specified drug delivery and site-specific drug bioactivation. Prodrugs can be designed to target specific enzymes or carriers by considering enzyme-substrate specificity or carrier-substrate specificity in order to overcome various undesirable drug properties. There are certain techniques which are used for tumor targeting such as Antibody Directed Enzyme Prodrug Therapy [ADEPT] Gene-Directed Enzyme Prodrug Therapy [GDEPT], Virus Directed Enzyme Prodrug Therapy [VDEPT] and Gene Prodrug Activation Therapy [GPAT]. Our review f

APA, Harvard, Vancouver, ISO, and other styles

34

Verstovsek, Srdan. "Therapeutic potential of JAK2 inhibitors." Hematology 2009, no. 1 (2009): 636–42. http://dx.doi.org/10.1182/asheducation-2009.1.636.

Full text

Abstract:

AbstractThe discovery of an activating tyrosine kinase mutation JAK2V617F in myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) has resulted in the development of JAK2 inhibitors, of which several are being evaluated in phase I/II clinical studies. It is important to recognize that because the V617F mutation is localized in a region outside the adenosine triphosphate (ATP)-binding pocket of JAK2 enzyme, ATP-competitive inhibitors of JAK2 kinase (like the current JAK2 inhibitors in the clinic) are not likely to discriminat

APA, Harvard, Vancouver, ISO, and other styles

35

Bhide, Yogesh S., Jitendra Y. Nehete, and Rajendra S. Bhambar. "Extraction, Characterization and Therapeutic Evaluation of Seeds of Phaseolus vulgaris L. for Inhibition of Carbohydrate Uptake." INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY 13, no. 01 (2023): 105–11. http://dx.doi.org/10.25258/ijddt.13.1.16.

Full text

Abstract:

Phaseolamin-rich beans, also known as -amylase inhibitor 1 (AI) bean. AI has shown promise in treating diabetes and obesity in human studies. Since enzymes speed up chemical reactions, thus they are needed for most biological processes. Humans have used catalysts for centuries. Chemical catalysis was a heavy, often-used method. The method lacks sensitivity, and catalysis requires high temperature and pressure. Enzymes may function under more benign settings than chemical catalysts. Enzymes speed up chemical processes more than chemical catalysts due to their specifi city. Enzymes are used in p

APA, Harvard, Vancouver, ISO, and other styles

36

Nes, W. David, Minu Chaudhuri, and David J. Leaver. "Druggable Sterol Metabolizing Enzymes in Infectious Diseases: Cell Targets to Therapeutic Leads." Biomolecules 14, no. 3 (2024): 249. http://dx.doi.org/10.3390/biom14030249.

Full text

Abstract:

Sterol biosynthesis via the mevalonate-isoprenoid pathway produces ergosterol (24β-methyl cholesta-5,7-dienol) necessary for growth in a wide-range of eukaryotic pathogenic organisms in eukaryotes, including the fungi, trypanosomes and amoebae, while their animal hosts synthesize a structurally less complicated product—cholesterol (cholest-5-enol). Because phyla-specific differences in sterol metabolizing enzyme architecture governs the binding and reaction properties of substrates and inhibitors while the order of sterol metabolizing enzymes involved in steroidogenesis determine the positioni

APA, Harvard, Vancouver, ISO, and other styles

37

Deng, Chao, Xianghai Li, Qianru Jin, and Deliang Yi. "Concentrically Encapsulated Dual-Enzyme Capsules for Synergistic Metabolic Disorder Redressing and Cytotoxic Intermediates Scavenging." Nanomaterials 12, no. 4 (2022): 625. http://dx.doi.org/10.3390/nano12040625.

Full text

Abstract:

Enzyme therapy has important implications for the treatment of metabolic disorders and biological detoxification. It remains challenging to prepare enzymatic nanoreactors with high therapeutic efficiency and low emission of cytotoxic reaction intermediates. Here, we propose a novel strategy for the preparation of enzymes-loaded polypeptide microcapsules (EPM) with concentrically encapsulated enzymes to achieve higher cascade reaction rates and minimal emission of cytotoxic intermediates. Mesoporous silica spheres (MSS) are used as a highly porous matrix to efficiently load a therapeutic enzyme

APA, Harvard, Vancouver, ISO, and other styles

38

de la Fuente, Miguel, Laura Lombardero, Alfonso Gómez-González, et al. "Enzyme Therapy: Current Challenges and Future Perspectives." International Journal of Molecular Sciences 22, no. 17 (2021): 9181. http://dx.doi.org/10.3390/ijms22179181.

Full text

Abstract:

In recent years, enzymes have risen as promising therapeutic tools for different pathologies, from metabolic deficiencies, such as fibrosis conditions, ocular pathologies or joint problems, to cancer or cardiovascular diseases. Treatments based on the catalytic activity of enzymes are able to convert a wide range of target molecules to restore the correct physiological metabolism. These treatments present several advantages compared to established therapeutic approaches thanks to their affinity and specificity properties. However, enzymes present some challenges, such as short in vivo half-lif

APA, Harvard, Vancouver, ISO, and other styles

39

Duskey, Jason Thomas, Federica da Ros, Ilaria Ottonelli, et al. "Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function." Molecules 25, no. 20 (2020): 4593. http://dx.doi.org/10.3390/molecules25204593.

Full text

Abstract:

Enzymes have gained attention for their role in numerous disease states, calling for research for their efficient delivery. Loading enzymes into polymeric nanoparticles to improve biodistribution, stability, and targeting in vivo has led the field with promising results, but these enzymes still suffer from a degradation effect during the formulation process that leads to lower kinetics and specific activity leading to a loss of therapeutic potential. Stabilizers, such as bovine serum albumin (BSA), can be beneficial, but the knowledge and understanding of their interaction with enzymes are not

APA, Harvard, Vancouver, ISO, and other styles

40

Fathi, Marziyeh, Azam Safary, and Jaleh Barar. "Therapeutic impacts of enzyme-responsive smart nanobiosystems." BioImpacts 10, no. 1 (2019): 1–4. http://dx.doi.org/10.15171/bi.2020.01.

Full text

Abstract:

An important arena of the sophisticated nanosystems (NSs) is the combination of the responsive features of NSs with the biocatalytic properties of enzymes. The development of such smart drug delivery systems (DDSs) has seminal effectiveness in targeting, imaging, and monitoring of cancer. These NSs can exhibit site-specific delivery of the toxic cargo in response to the endogenous/exogenous stimuli. Enzyme responsive/targeted DDSs display enhanced accumulation of cargo molecules in the tumor microenvironment (TME) with a spatiotemporal controlled-release behavior. Based on the unique features

APA, Harvard, Vancouver, ISO, and other styles

41

Sindhu, Rakesh K., Agnieszka Najda, Prabhjot Kaur, et al. "Potentiality of Nanoenzymes for Cancer Treatment and Other Diseases: Current Status and Future Challenges." Materials 14, no. 20 (2021): 5965. http://dx.doi.org/10.3390/ma14205965.

Full text

Abstract:

Studies from past years have observed various enzymes that are artificial, which are issued to mimic naturally occurring enzymes based on their function and structure. The nanozymes possess nanomaterials that resemble natural enzymes and are considered an innovative class. This innovative class has achieved a brilliant response from various developments and researchers owing to this unique property. In this regard, numerous nanomaterials are inspected as natural enzyme mimics for multiple types of applications, such as imaging, water treatment, therapeutics, and sensing. Nanozymes have nanomat

APA, Harvard, Vancouver, ISO, and other styles

42

Pyatakova, N. V., and I. S. Severina. "Soluble guanylate cyclase in the molecular mechanism underlying the therapeutic action of drugs." Biomeditsinskaya Khimiya 58, no. 1 (2012): 32–42. http://dx.doi.org/10.18097/pbmc20125801032.

Full text

Abstract:

The influence of ambroxol - a mucolytic drug - on the activity of human platelet soluble guanylate cyclase and rat lung soluble guanylate cyclase and activation of both enzymes by NO-donors (sodium nitroprusside and Sin-1) were investigated. Ambroxol in the concentration range from 0.1 to 10 μM had no effect on the basal activity of both enzymes. Ambroxol inhibited in a concentration-dependent manner the sodium nitroprusside-induced human platelet soluble guanylate cyclase and rat lung soluble guanylate cyclase with the IC50 values 3.9 and 2.1 μM, respectively. Ambroxol did not influence the s

APA, Harvard, Vancouver, ISO, and other styles

43

Shahri, Mahdi Abedinzadeh, Paniz Shirmast, Seyed Mohammad Ghafoori, and Jade Kenneth Forwood. "Deciphering the structure of a multi-drug resistant Acinetobacter baumannii short-chain dehydrogenase reductase." PLOS ONE 19, no. 2 (2024): e0297751. http://dx.doi.org/10.1371/journal.pone.0297751.

Full text

Abstract:

The rapidly increasing threat of multi-drug-resistant Acinetobacter baumannii infections globally, encompassing a range of clinical manifestations from skin and soft tissue infections to life-threatening conditions like meningitis and pneumonia, underscores an urgent need for novel therapeutic strategies. These infections, prevalent in both hospital and community settings, present a formidable challenge to the healthcare system due to the bacterium’s widespread nature and dwindling effective treatment options. Against this backdrop, the exploration of bacterial short-chain dehydrogenase reduct

APA, Harvard, Vancouver, ISO, and other styles

44

Gomez-Larrauri, Ana, Upasana Das Adhikari, Marta Aramburu-Nuñez, Antía Custodia, and Alberto Ouro. "Ceramide Metabolism Enzymes—Therapeutic Targets against Cancer." Medicina 57, no. 7 (2021): 729. http://dx.doi.org/10.3390/medicina57070729.

Full text

Abstract:

Sphingolipids are both structural molecules that are essential for cell architecture and second messengers that are involved in numerous cell functions. Ceramide is the central hub of sphingolipid metabolism. In addition to being the precursor of complex sphingolipids, ceramides induce cell cycle arrest and promote cell death and inflammation. At least some of the enzymes involved in the regulation of sphingolipid metabolism are altered in carcinogenesis, and some are targets for anticancer drugs. A number of scientific reports have shown how alterations in sphingolipid pools can affect cell p

APA, Harvard, Vancouver, ISO, and other styles

45

Lim, Key-Hwan, and Kwang-Hyun Baek. "Deubiquitinating Enzymes as Therapeutic Targets in Cancer." Current Pharmaceutical Design 19, no. 22 (2013): 4039–52. http://dx.doi.org/10.2174/1381612811319220013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Barghout, Samir H., and Aaron D. Schimmer. "E1 Enzymes as Therapeutic Targets in Cancer." Pharmacological Reviews 73, no. 1 (2020): 1–56. http://dx.doi.org/10.1124/pharmrev.120.000053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

ROSSI, J., and N. SARVER. "RNA enzymes (ribozymes) as antiviral therapeutic agents." Trends in Biotechnology 8 (1990): 179–83. http://dx.doi.org/10.1016/0167-7799(90)90169-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

López-Jaramillo, P., and J. P. Casas. "Blockade of endothelial enzymes: new therapeutic targets." Journal of Human Hypertension 16, S1 (2002): S100—S103. http://dx.doi.org/10.1038/sj.jhh.1001353.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Martins, M. B. F., A. P. V. Conçoives, J. C. Jorge, and M. E. M. Cruz. "Acylated enzymes: properties and potential therapeutic applications." European Journal of Pharmacology 183, no. 2 (1990): 401. http://dx.doi.org/10.1016/0014-2999(90)93282-u.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Almeida, Fausto, Julie M. Wolf, and Arturo Casadevall. "Virulence-Associated Enzymes of Cryptococcus neoformans." Eukaryotic Cell 14, no. 12 (2015): 1173–85. http://dx.doi.org/10.1128/ec.00103-15.

Full text

Abstract:

ABSTRACTEnzymes play key roles in fungal pathogenesis. Manipulation of enzyme expression or activity can significantly alter the infection process, and enzyme expression profiles can be a hallmark of disease. Hence, enzymes are worthy targets for better understanding pathogenesis and identifying new options for combatting fungal infections. Advances in genomics, proteomics, transcriptomics, and mass spectrometry have enabled the identification and characterization of new fungal enzymes. This review focuses on recent developments in the virulence-associated enzymes fromCryptococcus neoformans.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!